Literature DB >> 9333050

In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus.

Y C Chuang1, J W Liu, W C Ko, K Y Lin, J J Wu, K Y Huang.   

Abstract

We conducted time-kill studies to evaluate the inhibitory activities of either cefotaxime or minocycline alone and the two drugs in combination against a clinical strain of Vibrio vulnificus. The MICs of cefotaxime and minocycline were 0.03 and 0.06 microg/ml, respectively. When approximately 5 x 10(5) CFU of V. vulnificus per ml was incubated with cefotaxime at 0.03 or 0.05 microg/ml, the bacterial growth was inhibited during the initial 2 and 8 h, respectively. Thereafter, V. vulnificus regrew and the level of growth reached that of the control. Within the dose range of less than five times the MIC, the duration of the inhibitory effect of cefotaxime was proportional to its concentration. When minocycline at 0.015, 0.03, 0.045, and 0.06 microg/ml was used to evaluate the inhibitory effect, a similar trend was observed. Either antibiotic at a concentration of five times the MIC or greater prevented the regrowth of V. vulnificus for at least 48 h. When cefotaxime at 0.05 microg/ml and minocycline at 0.045 microg/ml were combined in the same culture, the inhibitory effect against V. vulnificus persisted for more than 48 h, with no regrowth noted. The use of a combination of these two antibiotics resulted in the reduction of growth by 6 orders of magnitude compared to the use of either of the two antibiotics alone, and the number of surviving organisms in the presence of the antibiotics combined was approximately 3 orders of magnitude less than that in the starting inoculum. We conclude that cefotaxime and minocycline acted synergistically in inhibiting V. vulnificus in vitro.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333050      PMCID: PMC164095     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Antibiotic combinations: the clinical relevance of synergy and antagonism.

Authors:  J J Rahal
Journal:  Medicine (Baltimore)       Date:  1978-03       Impact factor: 1.889

2.  Antibiotic therapy for Vibrio vulnificus infection.

Authors:  J G Morris; J Tenney
Journal:  JAMA       Date:  1985-02-22       Impact factor: 56.272

3.  Spontaneous Vibrio vulnificus peritonitis and primary sepsis in two patients with alcoholic cirrhosis.

Authors:  V Wongpaitoon; B Sathapatayavongs; R Prachaktam; S Bunyaratvej; S Kurathong
Journal:  Am J Gastroenterol       Date:  1985-09       Impact factor: 10.864

4.  Necrotizing soft-tissue infections caused by marine vibrios.

Authors:  R J Howard; M E Pessa; B H Brennaman; R Ramphal
Journal:  Surgery       Date:  1985-07       Impact factor: 3.982

5.  Clinical features and an epidemiological study of Vibrio vulnificus infections.

Authors:  C O Tacket; F Brenner; P A Blake
Journal:  J Infect Dis       Date:  1984-04       Impact factor: 5.226

6.  Disease caused by a marine Vibrio. Clinical characteristics and epidemiology.

Authors:  P A Blake; M H Merson; R E Weaver; D G Hollis; P C Heublein
Journal:  N Engl J Med       Date:  1979-01-04       Impact factor: 91.245

7.  Spectrum of Vibrio infections in a Gulf Coast community.

Authors:  J R Bonner; A S Coker; C R Berryman; H M Pollock
Journal:  Ann Intern Med       Date:  1983-10       Impact factor: 25.391

8.  Necrotising fasciitis caused by Vibrio vulnificus.

Authors:  M L Woo; W G Patrick; M T Simon; G L French
Journal:  J Clin Pathol       Date:  1984-11       Impact factor: 3.411

9.  Antibiotic efficacy against Vibrio vulnificus in the mouse: superiority of tetracycline.

Authors:  J H Bowdre; J H Hull; D M Cocchetto
Journal:  J Pharmacol Exp Ther       Date:  1983-06       Impact factor: 4.030

10.  Lactose-positive Vibrio in seawater: a cause of pneumonia and septicemia in a drowning victim.

Authors:  M T Kelly; D M Avery
Journal:  J Clin Microbiol       Date:  1980-03       Impact factor: 5.948

View more
  21 in total

1.  Necrotizing fasciitis caused by Vibrio vulnificus: epidemiology, clinical findings, treatment and prevention.

Authors:  Y-L Kuo; S-J Shieh; H-Y Chiu; J-W Lee
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 3.267

2.  In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.

Authors:  Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

3.  Bactericidal effects of toluidine blue-mediated photodynamic action on Vibrio vulnificus.

Authors:  Tak-Wah Wong; Yin-Yi Wang; Hamm-Ming Sheu; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus.

Authors:  Dong-Min Kim; Yong Lym; Sook Jin Jang; Hulin Han; Young Gi Kim; Choon-Hae Chung; Soon Pyo Hong
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Prognostic factor of mortality and its clinical implications in patients with necrotizing fasciitis caused by Vibrio vulnificus.

Authors:  Yao-Chou Lee; Lien-I Hor; Haw-Yen Chiu; Jing-Wei Lee; Shyh-Jou Shieh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-14       Impact factor: 3.267

6.  In vitro and in vivo combinations of cefotaxime and minocycline against Aeromonas hydrophila.

Authors:  W C Ko; H C Lee; Y C Chuang; S H Ten; C Y Su; J J Wu
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

7.  In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus.

Authors:  Hung-Jen Tang; Ming-Chung Chang; Wen-Chien Ko; Kun-Yen Huang; Chih-Lung Lee; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

8.  Predictors of mortality in skin and soft-tissue infections caused by Vibrio vulnificus.

Authors:  Tsai-Nung Kuo Chou; Wai-Nang Chao; Cheng Yang; Ruey-Hong Wong; Kwo-Chang Ueng; Shiuan-Chih Chen
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

9.  Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection.

Authors:  Y C Chuang; W C Ko; S T Wang; J W Liu; C F Kuo; J J Wu; K Y Huang
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Vibrio vulnificus Septicemia After Handling Tilapia Species Fish: A Canadian Case Report and Review.

Authors:  Donald C Vinh; Samira Mubareka; Bunmi Fatoye; Pierre Plourde; Pamela Orr
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-03       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.